characteristics and serologic determination of antibodies
play

Characteristics and Serologic Determination of Antibodies to High Frequency Antigens Nicole Thornton The International Blood Group Reference Laboratory Bristol, United Kingdom. 23 rd Regional Congress of the ISBT, June 2013 Academy Day

0 downloads 2 Views 432 KB Size Report
  1. Characteristics and Serologic Determination of Antibodies to High Frequency Antigens Nicole Thornton The International Blood Group Reference Laboratory Bristol, United Kingdom. 23 rd Regional Congress of the ISBT, June 2013 Academy Day

  2. Covering Today..... • Definition of a High Frequency Antigen (HFA) • Antibodies to HFAs – why difficult to investigate? • Show how we use knowledge of antibody characteristics to help determine the specificity of antibodies to HFAs • Supplementary serological methods • Case study • Summary & General Advice • (Rare Blood Provision)

  3. High Frequency Antigens • Also referred to as ‘high incidence’, ‘high prevalence’ and ‘public’ antigens • For HFA classification must have incidence of >90% but majority have an incidence of >99% • Lack of a HFA = rare phenotype Some almost ethnically exclusive • ~189 red blood cell antigens classified as HFAs by the ISBT

  4. Antibodies to HFAs • Difficult for routine laboratories to investigate • Invariably referred to a Reference laboratory • Antibody identification is required to:  Assess likely clinical significance  exclude underlying alloantibodies  to guide decisions regarding suitable blood for transfusion

  5. When to Consider the Possible Presence of an Antibody to a HFA • Screening cells and all cells of an additional identification cell panel are positive • Autologous control is negative 1. Antibody to HFA 2. Complex antibody mixture

  6. Ruling Out a Complex Mixture • Need to know patient’s “routine antigen” phenotypes Important! ABO, D, C, c, E, e, K, M, N, S, s, Fy a , Fy b , Jk a , Jk b • Modes of reactivity – use a range of techniques and temperatures to find the clues

  7. Antibody Characteristics • Important for all antibody identification • Essential for determining antibodies to HFAs  Mode of reactivity (technique, temperature)  Reactivity with enzyme treated/chemically modified cells (eg. papain, AET, trypsin)  Strength and consistency of reactivity  Appearance of agglutination  Ability to induce invitro haemolysis

  8. Investigating a Suspected Antibody to a HFA • All start in the same way All cells tested are positive

  9. All Cells Positive A B C D IAT IAT IAT IAT 18 ° C Panel Unt Pap Unt Pap Unt Pap Unt Pap Unt Cells 1 1 0 3 0 4 4 4 H 4 2 3 0 3 0 4 4 4 H 4 3 1 0 3 0 4 4 4 H 4 4 2 0 3 0 4 4 4 H 4 5 1 0 3 0 4 4 4 H 4 6 1 0 3 0 4 4 4 H 4 7 2 0 3 0 4 4 4 H 4 8 3 0 3 0 4 4 4 H 4 9 2 0 3 0 4 4 4 H 4 10 1 0 3 0 4 4 4 H 4 Auto 0 0 0 0 0 0 0 0 0 Anti-Ch/Rg, -Kn a /McC a , -Yk a

  10. All Cells Positive A B C D IAT IAT IAT IAT 18 ° C Panel Unt Pap Unt Pap Unt Pap Unt Pap Unt Cells 1 1 0 3 0 4 4 4 H 4 2 3 0 3 0 4 4 4 H 4 3 1 0 3 0 4 4 4 H 4 4 2 0 3 0 4 4 4 H 4 5 1 0 3 0 4 4 4 H 4 6 1 0 3 0 4 4 4 H 4 7 2 0 3 0 4 4 4 H 4 8 3 0 3 0 4 4 4 H 4 9 2 0 3 0 4 4 4 H 4 10 1 0 3 0 4 4 4 H 4 Auto 0 0 0 0 0 0 0 0 0 Anti-JMH, -In b , -Ge2, -Yt a

  11. All Cells Positive A B C D IAT IAT IAT IAT 18 ° C Panel Unt Pap Unt Pap Unt Pap Unt Pap Unt Cells 1 1 0 3 0 4 4 4 H 4 2 3 0 3 0 4 4 4 H 4 3 1 0 3 0 4 4 4 H 4 4 2 0 3 0 4 4 4 H 4 5 1 0 3 0 4 4 4 H 4 6 1 0 3 0 4 4 4 H 4 7 2 0 3 0 4 4 4 H 4 8 3 0 3 0 4 4 4 H 4 9 2 0 3 0 4 4 4 H 4 10 1 0 3 0 4 4 4 H 4 Auto 0 0 0 0 0 0 0 0 0 Rh, Kell, Jk, Scianna, Colton, Dombrock, Diego, Cromer

  12. All Cells Positive A B C D IAT IAT IAT IAT 18 ° C Panel Unt Pap Unt Pap Unt Pap Unt Pap Unt Cells 1 1 0 3 0 4 4 4 H 4 2 3 0 3 0 4 4 4 H 4 3 1 0 3 0 4 4 4 H 4 4 2 0 3 0 4 4 4 H 4 5 1 0 3 0 4 4 4 H 4 6 1 0 3 0 4 4 4 H 4 7 2 0 3 0 4 4 4 H 4 8 3 0 3 0 4 4 4 H 4 9 2 0 3 0 4 4 4 H 4 10 1 0 3 0 4 4 4 H 4 Auto 0 0 0 0 0 0 0 0 0 Anti-Vel, -PP1P k , -H (made in O h )

  13. What Next? Options 1 Screen the patient’s cells for selected HFAs Match selected rare phenotype & null 2 cells against patient’s plasma selection based on antibody characteristics observed in initial panels and any information regarding the patient’s ethnicity

  14. Option 2 Matching rare phenotype & null cells Caution needed • Underlying antibodies may be present • Beware ABO!

  15. Option 1 & 2 Negative Found! • Type patient’s cells for relevant antigen(s) • Match further examples (if possible) in order to exclude underlying antibodies All positive

  16. Supplementary Tests Eluate • Make an eluate from Gp O ‘antigen matched’ cells  eliminates ABO incompatibility issues  isolates antibody to HFA  can match rare phenotype cells of any ABO group and without worry of contaminating antibodies to ‘common antigens’

  17. Supplementary Tests Enzymes Papain Trypsin Chymotrypsin Pronase AET Knops +/- - - + - Ch/Rg - - - - + Cromer + + - + (+) Vel + + + + + Lan + + + + + Kell + + + + - JMH - - - - - LW + + + - - Examples of effect of enzyme treatment/chemical modification

  18. Supplementary Tests C4 coated cells A IAT Panel Cells Unt Pap • Ch/Rg are plasma antigens, located 1 1 0 on complement receptor C4 2 3 0 • C4 coat cells in vitro → increased 3 1 0 amounts of Ch/Rg 4 2 0 5 1 0 • Test in parallel with uncoated cells 6 1 0 • Strong reaction = instant indication 7 2 0 of anti-Ch/Rg specificity 8 3 0 9 2 0 Uncoated C4 coated 10 10 1 1 0 5 Auto 0 0

  19. Supplementary Tests Inhibitions • Anti-Ch/Rg can be inhibited by C4 in plasma • Soluble recombinant blood group proteins (sRGB) are another way of determining if a supected blood group protein is the culprit  Incubate patient’s plasma with sRBG in parallel with a diluent control  Test both with known positive cells and if reactivity is diminished or eliminated in the presence of a positive diluent control, indicates antibody has been inhibited  particularly useful for CR1-related antibodies

  20. Supplementary Tests MAIEA assay • Monoclonal Antibody Immobilisation of Erythrocyte Antigens Mabs specific for  suspected RBC membrane protein  Positive result indicates human antibody has bound to targeted protein  Can also be used as competitive binding assay to map epitopes

  21. Supplementary Tests MAIEA assay  Useful when particular blood group system is suspected (usually based on enzyme studies)  Economical on plasma  Particularly effective for identifying CR1-related antibodies and for helping to assign novel specificities  We currently use MAIEA for: Knops, Cromer, Lutheran, Kell, Yt and the Indian system  Lu21, INFI & INJA HFA’s discovered with help from MAIEA

  22. Supplementary Tests Gene sequencing • Clues from serology → which gene to target

  23. Case Study • Chinese patient, samples Panel IAT Cells referred from Australia Unt Pap 1 3 3 • All cells positive 2 3 3 3 3 3 • Typed cells for HFAs, all 4 3 3 positive 5 3 3 6 3 3 • Matched selected null 7 3 3 8 3 3 cells, all positive 9 3 3 10 3 3 Auto 0 0

  24. Case Study Papain Trypsin Chymotrypsin Pronase AET Knops +/- - - + - Ch/Rg - - - - + Cromer + + - + (+) Vel + + + + + Lan + + + + + Kell + + + + - JMH - - - - - Patient + + - + (+) Clue!

  25. Case Study • Soluble recombinant DAF protein – antibody inhibited! • Typed patient’s cells for Cromer HFAs (in small batches based on rarity of antibody) UMC- • No UMC- cells for matching • One IFC- compatible, one Dr(a-) weakly incompatible • DAF sequencing revealed homozygous mutation in exon 6, 749C>T encoding Thr250Met in DAF protein. Known to be associated with UMC- phenotype • Mother and only sibling both heterozygous

  26. Take Home Points • Identification of antibodies to HFAs is time consuming and complex → delay in patient care • Observing the clues is essential to a timely resolution • Knowledge of different antibody characteristics is key to recognising the clues – get to know them! • The “gut feeling” of an experienced serologist is invaluable

  27. General Advice • Occasionally antibodies do not do as expected! • Very rare specificities – the described characteristics are based on limited observations • Use the expected characteristics as a GUIDE not an absolute! Finally……… • Successful determination of antibodies to HFAs requires competency in manual serological techniques. A dying art.

  28. Thank You

Recommend Documents


determination of thermodynmic surface characteristics of
DETERMINATION OF THERMODYNMIC SURFACE

18 TH INTERNATIONAL CONFERENCE ON COMPOSITE MATERIALS DETERMINATION OF

sub topics
Sub-topics Chemical characterization

Sub-topics Chemical characterization Sorption-Desorption Characteristics

sub topics
Sub-topics Chemical characterization

Sub-topics Chemical characterization Sorption-Desorption Characteristics

sub topics
Sub-topics Chemical characterization

15.10.2018 Lecture No. 21 Lecture

clinical presentation of celiac disease and the
Clinical presentation of celiac disease

See discussions, stats, and author profiles for this publication at:

resource utilization
Resource Utilization and Costs

Resource Utilization and Costs Associated with Serologic Testing Alyssa

guideline on biosimilar monoclonal antibodies
Guideline on Biosimilar Monoclonal

Guideline on Biosimilar Monoclonal Antibodies Non-clinical issues A

antibodies and antigens antibodies and antigens
Antibodies and Antigens Antibodies and

Antibodies and Antigens Antibodies and Antigens Your body s natural defense

bioventix presentation october 2019
Bioventix Presentation: October 2019

1 Bioventix Presentation: October 2019 Bioventix & antibodies for blood

bioventix presentation march 2018
Bioventix Presentation: March 2018

1 Bioventix Presentation: March 2018 Bioventix & antibodies for blood

kansas hen 2 0 collaborative meeting november 18 2015
Kansas HEN 2.0 Collaborative Meeting

Kansas HEN 2.0 Collaborative Meeting November 18, 2015 Reducing Clostridium

antimicrobial stewardship in livestock and companion
Antimicrobial stewardship in livestock

Antimicrobial stewardship in livestock and companion animals: the why and the

advances in biomarker testing for sepsis and
ADVANCES IN BIOMARKER TESTING FOR

ADVANCES IN BIOMARKER TESTING FOR SEPSIS AND BACTERIAL INFECTIONS ERIC H

variability in emergency physician care for severe sepsis
Variability in Emergency Physician

Variability in Emergency Physician Care for Severe Sepsis: How do we Measure

1 hour to antibiotics audit
1 hour to antibiotics audit:

Acute Oncology Service 1 hour to antibiotics audit: Presentation Title

odds and ends
Odds and Ends Javad Parvizi MD, FRCS

Odds and Ends Javad Parvizi MD, FRCS Jam es Edwards Professor of Orthopaedics

how should antibodies against mab therapeutics be
How should antibodies against mAb

How should antibodies against mAb therapeutics be assessed? Meenu Wadhwa

investor presentation 2018
INVESTOR PRESENTATION 2018 IMMUN

TSX.V : IPA OTC : IPATF INVESTOR PRESENTATION 2018 IMMUN UNOPR OPRECI

antibody development services for the pharma amp
ANTIBODY DEVELOPMENT SERVICES FOR THE

ANTIBODY DEVELOPMENT SERVICES FOR THE PHARMA & DIAGNOSTIC SECTORS INVESTOR

antibodies that guarantee
antibodies that guarantee reproducible

Getting to recombinant antibodies that guarantee reproducible research

mon onoc oclonal an antibody ag against inorgani nic p
Mon onoc oclonal An Antibody Ag

Mon onoc oclonal An Antibody Ag Against Inorgani nic P Polypho phospha